Zadeo Cimarosti

Discovery Process and Pharmacological Characterization of 2-(<i>S</i>)-(4-Fluoro-2-methylphenyl)piperazine-1-carboxylic Acid [1-(<i>R</i>)-(3,5-Bis-trifluoromethylphenyl)ethyl]methylamide (Vestipitant) as a Potent, Selective, and Orally Active NK₁ Receptor Antagonist

Romano Di Fabio, Cristiana Griffante, Giuseppe Alvaro et al. · Journal of Medicinal Chemistry · 2009 · 54 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Application of Quality by Design Principles to Support Development of a Control Strategy for the Control of Genotoxic Impurities in the Manufacturing Process of a Drug Substance

Zadeo Cimarosti, Fernando Bravo, P. Stonestreet et al. · Organic Process Research & Development · 2009 · 45 citations

Pharmacy, Toxicology, Pharmaceutical Manufacturing +16

Discovery and Biological Characterization of (2<i>R</i>,4<i>S</i>)-1′-Acetyl-<i>N</i>-{(1<i>R</i>)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-<i>N</i>-methyl-4,4′-bipiperidine-1-carboxamide as a New Potent and Selective Neurokinin 1 (NK₁) Receptor Antagonist Clinical Candidate

Romano Di Fabio, Giuseppe Alvaro, Cristiana Griffante et al. · Journal of Medicinal Chemistry · 2011 · 36 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

Application of Quality by Design Principles for the Definition of a Robust Crystallization Process for Casopitant Mesylate

C. Castagnoli, Mohammed Yahyah, Zadeo Cimarosti et al. · Organic Process Research & Development · 2010 · 35 citations

Pharmacy, Pharmaceutics, Pharmacology +13

Application of the QbD Principles in the Development of the Casopitant Mesylate Manufacturing Process. Process Research Studies for the Definition of the Control Strategy of some Drug Substance-CQAs for Stages 2a, 2b, and 2c

Zadeo Cimarosti, Fernando Bravo, Damiano Castoldi et al. · Organic Process Research & Development · 2010 · 26 citations

Pharmacy, Pharmacology, Regulatory Pharmacy +17